NasdaqGM:NAMSBiotechs
NewAmsterdam Expands Obicetrapib Trials Into Diabetes And Alzheimer’s As Losses Mount
NewAmsterdam Pharma has begun late stage RUBENS Phase 3 trials of obicetrapib in patients with Type 2 diabetes and metabolic syndrome.
The company also plans to launch a new trial of obicetrapib in early Alzheimer's disease.
These programs expand obicetrapib's potential use into major cardiometabolic and neurological conditions.
For investors watching NasdaqGM:NAMS, these trial moves come as the stock trades at $35.24 and has returned 75.8% over the past year and 237.2% over the past five...